PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently appointed Glenn Reicin as chief financial officer, effective immediately, and reaffirmed its 2026 net product revenue guidance of $1.0 billion to $1.04 billion, the company announced.
Reicin joins Harmony’s executive team and will oversee financial planning, accounting, treasury, investor relations, and risk management.
The company said the appointment supports its strategic growth plans and financial operations as it targets more than $1 billion in Wakix sales in 2026.
Reicin most recently served as chief financial officer at Eccogene, where he helped prepare the company for a potential initial public offering and built its financial infrastructure.
He previously held roles as chief financial officer and chief operating officer at Alladapt Immunotherapeutics, where he oversaw fundraising and operational development.
Reicin began his career as a research analyst at Morgan Stanley and later served as managing director at Skyline Ventures.
Harmony Chief Executive Officer Jeffrey Dayno said Reicin’s experience in capital markets and financial strategy will support the company’s growth initiatives.
Dayno also thanked outgoing executive Sandip Kapadia for his contributions to the company’s financial operations.
Harmony Biosciences develops therapies for rare neurological diseases and is headquartered in Plymouth Meeting, Pennsylvania.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.